SMSanna Mononen

Sanna Mononen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanna Mononen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Johanna Arola

    Faculty of Medicine University of Helsinki Helsinki Finland

    2 shared publications
  • Tiina Vesterinen

    HUS Diagnostic Centre, Department of Pathology, Helsinki University Hospital and University of Helsinki , Helsinki

    2 shared publications
  • Aija Knuuttila

    F Department of Pulmonary Medicine, Heart and Lung Center, and Cancer Center , University of Helsinki and Helsinki University Hospital , Helsinki , Finland

    1 shared publication
  • Caj Haglund

    University of Helsinki

    1 shared publication
  • Harri Mustonen

    Abdominal Center, Department of Gastrointestinal Surgery, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland

    1 shared publication
  • Ilkka Ilonen

    Departments of Oncology and Hematology, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

    1 shared publication

Latest Publications

  • Open Access

    Absence of orthopaedia homeobox protein (OTP) expression is associated with disease spread and adverse outcome in pulmonary carcinoid tumour patients

    by Jenni Niinimäki, Sanna Mononen, Tuomas Kaprio, Johanna Arola, Tiina Vesterinen

    Pulmonary carcinoid (PC) tumours typically have a good prognosis, although metastases occur, and the disease may progress after a long period of time. Expression of orthopaedia homeobox protein (OTP) has been recognized as a possible independent prognostic marker in PCs. Immunohistochemical (IHC) OTP expression has been associated with better prognosis, but the staining has yet to be implemented in routine clinical diagnostics. In response to this, two new monoclonal OTP antibodies were recently developed. This retrospective study included 164 PC patients operated on at Helsinki University Hospital between 1990 and 2020. Tissue microarray slides, prepared from formalin-fixed and paraffin-embedded primary tumour samples, were stained with OTP IHC using one polyclonal and two novel monoclonal antibodies. Absence of OTP expression was associated with a shorter disease-specific survival (DSS) and disease progression (p < 0.001). Patients without OTP expression had a 5-year DSS of 73–79%, whereas 5-year DSS was 91–94% with OTP expression, depending on the primary antibody. In a univariable Cox regression model, absence of OTP expression was associated with adverse outcome along with atypical histological subtype, metastatic disease, Ki-67 proliferation index > 1%, and larger tumour size. In a multivariable Cox regression model, only absence of OTP expression and lymph node involvement at the time of diagnosis were associated with risk of worse prognosis. All three antibodies showed good concordance with each other. Our findings support the role of OTP as an independent prognostic marker in PCs and applicability of IHC staining in routine clinical use with novel monoclonal antibodies.


  • Open Access

    Clinicopathological indicators of survival among patients with pulmonary carcinoid tumor

    by Tiina Vesterinen, Sanna Mononen, Kaisa Salmenkivi, Harri Mustonen, Jari Räsänen, Jarmo A. Salo, Ilkka Ilonen, Aija Knuuttila, Caj Haglund, Johanna Arola

    Background: Pulmonary carcinoids (PC) are rare malignant neoplasms that cover approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor. The aim of this study was to evaluate if other tissue or clinical features are associated with patient outcomes. Material and methods: We retrospectively reviewed clinical records of 133 PC patients who underwent operation in the Helsinki University Hospital between 1990 and 2013. Tissue specimens were re-evaluated, processed into tissue microarray format and stained immunohistochemically with serotonin, calcitonin, adrenocorticotropic hormone (ACTH), thyroid transcription factor-1 (TTF-1) and Ki-67. Survival and risk analyses were performed. Results: Based on histology, 75% (n = 100) of the tumors were TCs and 25% (n = 33) ACs. TCs had higher 10-year disease-specific survival (DSS) rate than ACs (99% (95% CI, 93–100%) for TCs vs. 82% (95% CI, 61–92%) for ACs). Hormonally active tumors expressing serotonin, calcitonin or ACTH were noted in 53% of the specimens but hormonal expression was not associated with DSS. TTF-1 was positive in 78% of the specimens but was not associated with DSS. Ki-67 index varied between p = .004). The presence of metastatic disease (p = .001), tumor size ≥30 mm (p = .021) and atypical histology (p = .011) were also associated with disease-specific mortality. Conclusions: We conclude that PCs are uncommon tumors. When resected, the long-term survival is in general favorable. In this consecutive, single-institution cohort of patients, presence of metastatic disease, tumor size, histological subtype and Ki-67 index were associated with shorter disease-specific survival. As TC and AC have different clinical behaviors, the correct tumor classification at the time of diagnosis is a necessity.